In this case, despite the absence of standardized CLDN18.2 testing results (due to early limitations in medical conditions), the patient exhibited a significant response to LM302, with complete regression of lymph node metastases. Here, CLDN18 is linked to metastatic malignant neoplasm in the lymph nodes.